Venture Capital

Advanced aerial surveys reveal massive, untapped deposits of copper and nickel in Canada's far north, potentially rivaling the world's largest mineral reserves.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

With new leadership and a debt-free balance sheet, EnviroGold pivots to commercialize its mine waste tech, tapping into global critical minerals demand.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

While the design world embraces white, one company is investing in a full-spectrum color technology, building a resilient market niche.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

A smart appliance company is upending global expansion by proving that listening to local communities is the key to becoming a brand that truly matters.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Promising long-term data and key regulatory wins position Wugen's allogeneic therapy to disrupt the challenging T-cell cancer treatment landscape.